Darolutamide in Combination with Radium-223 Exhibits Synergistic Antitumor Efficacy in LNCaP Prostate Cancer Models
International Journal of Molecular Sciences · 21.12.2024 · 25 (24) · 13672
DOI: 10.3390/ijms252413672 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 21.12.2024. Verfasst von Urs B Hagemann und 9 weiteren Autor:innen. Beteiligte Einrichtung: Bayer AG, Research & Development, Pharmaceuticals, 13353 Berlin, Germany. Hauptthemen laut MEDLINE: Radium, Pyrazoles, Xenograft Model Antitumor Assays. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bayer AG.
Abstract (Originalsprache)
Despite treatment, prostate cancer commonly progresses into castration-resistant prostate cancer (CRPC), which remains largely incurable, requiring the development of new interventions. Darolutamide is an orally administered second-generation androgen receptor inhibitor indicated for patients with non-metastatic CRPC or metastatic hormone-sensitive prostate cancer. Here, we evaluated the effect of androgen receptor (AR) inhibition by darolutamide in combination with DNA double-strand-break-inducing targeted radium-223 alpha therapy in vitro and in an intratibial LNCaP xenograft model mimicking prostate cancer metastasized to bone. The results highlight the synergistic antitumor efficacy of darolutamide in combination with radium-223 both in vitro and in vivo. This effect was most likely driven by the downregulation of genes involved in DDR signaling, which was demonstrated in vitro by a gene set enrichment analysis. The combination treatment also reduced pathological tumor-induced effects in bone by decreasing the number of osteoblasts and osteoclasts and reducing abnormal bone formation in tumor-bearing bone. Additionally, it was shown that darolutamide does not affect the uptake of radium-223 into bone tissue. These results support the investigation of darolutamide in combination with radium-223 for the treatment of patients with CRPC metastasized to bone.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Bayer AG, Research & Development, Pharmaceuticals, 13353 Berlin, Germany.
- Pharmatest Services Ltd., 20520 Turku, Finland.
- Aurexel Life Sciences Ltd., 21240 Askainen, Finland.
- Inoi Oy, 20100 Turku, Finland.
- Institute of Biomedicine, University of Turku, 20520 Turku, Finland.
ORCID-Profile: Mari I Suominen, Andreas Schlicker, Matias Knuuttila, Esa Alhoniemi, Sanna-Maria Käkönen, Bernard Haendler
Förderung
- Bayer AG
Zitieren
APA
Hagemann, U. B., Schatz, C. A., Suominen, M. I., Schlicker, A., Knuuttila, M., Wilson, T., Alhoniemi, E., Käkönen, S. M., Haendler, B., & Scholz, A. (2024). Darolutamide in Combination with Radium-223 Exhibits Synergistic Antitumor Efficacy in LNCaP Prostate Cancer Models. International Journal of Molecular Sciences, 25(24), 13672. https://doi.org/10.3390/ijms252413672
Vancouver
Hagemann UB, Schatz CA, Suominen MI, Schlicker A, Knuuttila M, Wilson T, et al. Darolutamide in Combination with Radium-223 Exhibits Synergistic Antitumor Efficacy in LNCaP Prostate Cancer Models. International Journal of Molecular Sciences. 2024;25(24):13672. doi:10.3390/ijms252413672
BibTeX
@article{Hagemann2024,
author = {Hagemann, Urs B and Schatz, Christoph A and Suominen, Mari I and Schlicker, Andreas and Knuuttila, Matias and Wilson, Timothy and Alhoniemi, Esa and Käkönen, Sanna-Maria and Haendler, Bernard and Scholz, Arne},
title = {Darolutamide in Combination with Radium-223 Exhibits Synergistic Antitumor Efficacy in LNCaP Prostate Cancer Models},
journal = {International Journal of Molecular Sciences},
year = {2024},
volume = {25},
number = {24},
pages = {13672},
doi = {10.3390/ijms252413672}
}
EUVIMED